Approximately 2,500 pediatric hematopoietic cell transplants (HCTs), most of which are allogeneic, are performed annually in the United States for life-threatening malignant and nonmalignant conditions. Although HCT is undertaken with curative intent, post-HCT complications limit successful outcomes, with pulmonary dysfunction representing the leading cause of nonrelapse mortality. To better understand, predict, prevent, and/or treat pulmonary complications after HCT, a multidisciplinary group of 33 experts met in a 2-day National Institutes of Health Workshop to identify knowledge gaps and research strategies most likely to improve outcomes. This summary of Workshop deliberations outlines the consensus focus areas for future research.
Bibliographical noteFunding Information:
Supported by the National Heart, Lung, Blood Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Cancer Institute, U.S. National Institutes of Health.
Copyright © 2021 by the American Thoracic Society
Copyright 2021 Elsevier B.V., All rights reserved.
- Acute respiratory distress syndrome
- Hematopoietic cell transplantation
- Pulmonary complications
- Respiratory failure
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural